This is a preview of subscription content, log in via an institution to check access.
Reference
Chan S, et al. Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis. 22nd World Congress on Gastrointestinal Cancer : abstr. P-259, 1 Jul 2020. Available from: URL: https://www.sciencedirect.com/science/article/pii/S092375342039640X
Rights and permissions
About this article
Cite this article
Pembrolizumab too costly as 2nd-line therapy of hepatocellular carcinoma. PharmacoEcon Outcomes News 859, 23 (2020). https://doi.org/10.1007/s40274-020-7032-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7032-x